Mankind Pharma Expands Chronic Therapy Portfolio with Rivotril Acquisition

Mankind Pharma has acquired the Rivotril brand from Roche for the Indian market. This acquisition enhances their focus on chronic therapies, especially in the CNS area, and allows them to manufacture and distribute the widely prescribed clonazepam across India.

Mankind Pharma announced on Wednesday its acquisition of the Rivotril brand from Roche for the Indian market. The deal grants Mankind exclusive rights to manufacture, market, and distribute Rivotril, an innovator brand of clonazepam, known for its efficacy in treating neurological and psychiatric conditions.

This strategic acquisition aligns with Mankind's commitment to strengthen their presence in chronic and specialty therapies. The company has steadily expanded its footprint in these segments through new launches, strategic partnerships, and portfolio enhancements across key therapeutic areas.

According to Atish Majumdar, Senior President of Sales & Marketing for Mankind Pharma Specialty Business, the addition of Rivotril will fortify their CNS portfolio, offering increased treatment options for patients and addressing the evolving needs of specialists in managing neurological conditions.

(With inputs from agencies.)